M&A Deal Summary |
|
---|---|
Date | 2021-05-04 |
Target | Kuur Therapeutics |
Sector | Life Science |
Buyer(s) | Athenex |
Deal Type | Add-on Acquisition |
Deal Value | 185M USD |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2003 |
Sector | Life Science |
Employees | 652 |
Revenue | 120M USD (2021) |
Athenex is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer. Athenex has organized around three platforms, including an Oncology Innovation Platform, a Commercial Platform, and a Global Supply Chain Platform. The Company’s current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) Cell therapy, and (4) Arginine deprivation therapy. Athenex was founded in 2003 and is based in Buffalo, New york.
DEAL STATS | # |
---|---|
Overall | 2 of 2 |
Sector (Life Science) | 2 of 2 |
Type (Add-on Acquisition) | 2 of 2 |
Country (United Kingdom) | 1 of 1 |
Year (2021) | 1 of 1 |
Size (of disclosed) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2014-09-09 |
QuaDPharma
New York, New York, United States QuaDPharma specializing in pharmaceutical manufacturing, analytical, and support services to the pharmaceutical and biotech industries. |
Buy | - |